773 related articles for article (PubMed ID: 12424539)
1. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
[TBL] [Abstract][Full Text] [Related]
2. High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma.
Blystad A; Kvalheim G; Torlakovic E; Holte H; Jacobsen E; Beiske K; Vâlerhaugen H; Lenschow E; Kvaloy S
Bone Marrow Transplant; 1999 Oct; 24(8):865-72. PubMed ID: 10516698
[TBL] [Abstract][Full Text] [Related]
3. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
[TBL] [Abstract][Full Text] [Related]
4. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
5. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
[TBL] [Abstract][Full Text] [Related]
7. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J
Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727
[TBL] [Abstract][Full Text] [Related]
8. Autologous bone marrow transplantation for progressive non-Hodgkin's lymphoma: clinical impact of immunophenotype and in vitro purging.
Weisdorf DJ; Haake R; Miller WJ; McGlave PB; LeBien TW; Vallera DA; Lasky LC; Kim TH; Peterson BA; Ramsay NK
Bone Marrow Transplant; 1991 Aug; 8(2):135-42. PubMed ID: 1933055
[TBL] [Abstract][Full Text] [Related]
9. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement.
Bird JM; Luger S; Mangan P; Edelstein M; Silberstein L; Powlis W; Ball J; Schultz DJ; Stadtmauer EA
Bone Marrow Transplant; 1996 Aug; 18(2):309-13. PubMed ID: 8864439
[TBL] [Abstract][Full Text] [Related]
10. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
12. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival.
González-Barca E; Fernández de Sevilla A; Domingo-Claros A; Romagosa V; Martín-Henao GA; De Sanjose S; Carmona M; Petit J; García J; Grañena A
Bone Marrow Transplant; 2000 Nov; 26(10):1051-6. PubMed ID: 11108302
[TBL] [Abstract][Full Text] [Related]
14. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
[TBL] [Abstract][Full Text] [Related]
15. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
16. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
17. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
Ball ED; Wilson J; Phelps V; Neudorf S
Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
[TBL] [Abstract][Full Text] [Related]
19. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
[TBL] [Abstract][Full Text] [Related]
20. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]